Activation of inducible nitric oxide synthase increases MMP-2 and MMP-9 levels in ApoE-knockout mice

Tokai Journal of Experimental and Clinical Medicine

Volumn 33, Issue 1, 2008, Pages 28-34

  Chen, Yi ^a   Aratani, Yasuaki ^b   Osawa, Toshihiko ^c   Fukuyama, Naoto ^a   Tsuji, Chizuko ^a   Nakazawa, Hiroe ^a  

^a TOKAI UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY   (Japan)

Author keywords

ApoE; Atheroma; Knockout mice; Metalloproteinase; Nitric oxide

Indexed keywords

3 NITROTYROSINE; APOLIPOPROTEIN E; COLLAGEN; GELATINASE A; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROMA; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL DIET; CONTROLLED STUDY; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; LIPID BLOOD LEVEL; MOUSE; NONHUMAN; PATHOGENESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ZYMOGRAPHY;

ANIMALS; AORTA; APOLIPOPROTEINS E; CHOLESTEROL, DIETARY; COLLAGEN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME ACTIVATION; IMMUNOHISTOCHEMISTRY; LIPIDS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIUM; NITRIC OXIDE SYNTHASE TYPE II; PLAQUE, ATHEROSCLEROTIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 57149118656     PISSN: 03850005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 352: 1685-1695.
2. Shah PK. Pathophysiology of coronary thrombosis: role of plaque rupture and plaque erosion. Prog Cardiovasc Dis. 2002; 44: 357-368.
3. Sukhova GK, Schonbeck U, Rabkin E, Schoen FJ, Poole AR, Billinghurst RC, Libby P. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation. 1999; 99: 2503-2509.
4. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003; 92: 827-839.
5. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994; 94: 2493-2503.
6. Godin D, Ivan E, Johnson C, Magid R, Galis ZS. Remodeling of carotid artery is associated with increased expression of matrix metalloproteinases in mouse blood flow cessation model. Circulation. 2000; 102: 2861-2866.
7. Newby AC, Johnson JL. Genetic strategies to elucidate the roles of matrix metalloproteinases in atherosclerotic plaque growth and stability. Circ Res. 2005; 97: 958-960.
8. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev. 2005; 85: 1-31.
9. Johnson JL, George SJ, Newby AC, Jackson CL. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci U S A. 2005; 102: 15575-15580.
10. Gough PJ, Gomez IG, Wille PT, Raines EW. Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J Clin Invest. 2006; 116: 59-69.
11. Choi ET, Collins ET, Marine LA, Uberti MG, Uchida H, Leidenfrost JE et al. Matrix metalloproteinase-9 modulation by resident arterial cells is responsible for injury-induced accelerated atherosclerotic plaque development in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2005; 25: 1020-1025.
12. Kuhlencordt PJ, Gyurko R, Han F, Scherrer-Crosbie M, Aretz TH, Hajjar R, et al. Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation. 2001; 104: 448-454.
13. Napoli C, de Nigris F, Williams-Ignarro S, Pignalosa O, Sica V, Ignarro LJ. Nitric oxide and atherosclerosis: an update. Nitric Oxide. 2006; 15: 265-279.
14. Hayashi T, Sumi D, Juliet PA, Matsui-Hirai H, Asai-Tanaka Y, Kano H, et al. Gene transfer of endothelial NO synthase, but not eNOS plus inducible NOS, regressed atherosclerosis in rabbits. Cardiovasc Res. 2004; 61: 339-351.
15. Detmers PA, Hernandez M, Mudgett J, Hassing H, Burton C, Mundt S, et al. Deficiency in inducible nitric oxide synthase results in reduced atherosclerosis in apolipoprotein E-deficient mice. J Immunol. 2000; 165: 3430-3435.
16. Kuhlencordt PJ, Chen J, Han F, Astern J, Huang PL. Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice. Circulation. 2001; 103: 3099-3104.
17. Koglin J, Glysing Jensen T, Mudgett JS, Russell ME. Exacerbated transplant arteriosclerosis in inducible nitric oxide-deficient mice. Circulation. 1998; 97: 2059-2065.
18. Niu XL, Yang X, Hoshiai K, Tanaka K, Sawamura S, Koga Y, et al. Inducible Nitric Oxide Synthase Deficiency Does Not Affect the Susceptibility of Mice to Atherosclerosis but Increases Collagen Content in Lesions. Circulation. 2001;103:1115-1120.
19. Beckmann JS, Ye YZ, Anderson PG, Chen J, Accavitti MA, Tarpey MM, et al. Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biol Chem Hoppe Seyler. 1994; 375: 81-88.
20. Wu J, Akaike T, Hayashida K, Okamoto T, Okuyama A, Maeda H. Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinases. Jpn J Cancer Res. 2001; 92: 439-451.
21. Migita K, Maeda Y, Abiru S, Komori A, Yokoyama T, Takii Y, et al. Peroxynitrite-mediated matrix metalloproteinase-2 activation in human hepatic stellate cells. FEBS Lett. 2005; 579: 3119-3125.
22. Wang W, Sawicki G, Schulz R. Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. Cardiovasc Res. 2002; 53: 165-174.
23. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992; 258: 468-471.
24. Chen Y, Hozawa S, Sawamura S, Sato S, Fukuyama N, Tsuji C, et al. Deficiency of inducible nitric oxide synthase exacerbates hepatic fibrosis in mice fed high-fat diet. Biochem Biophys Res Commun. 2005; 326: 45-51.
25. Gough PJ, Raines EW. Gene therapy of apolipoprotein E-deficient mice using a novel macrophage-specific retroviral vector. Blood. 2003; 101: 485-491.
26. Luttun A, Lutgens E, Manderveld A, Maris K, Collen D, Carmeliet P, Moons L. Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation. 2004; 109: 1408-1414.
27. Chen J, Kuhlencordt P, Urano F, Ichinose H, Astern J, Huang PL. Effects of chronic treatment with L-arginine on atherosclerosis in apoE knockout and apoE/inducible NO synthase double-knockout mice. Arterioscler Thromb Vasc Biol. 2003; 23: 97-103.
28. Herman MP, Sukhova GK, Kisiel W, Foster D, Kehry MR, Libby P, et al. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J Clin Invest. 2001; 107: 1117-1126.
29. Major TC, Liang L, Lu X, Rosebury W, Bocan TM. Extracellular matrix metalloproteinase inducer (EMMPRIN) is induced upon monocyte differentiation and is expressed in human atheroma. Arterioscler Thromb Vasc Biol. 2002; 22: 1200-1207.